Literature DB >> 31278384

Atherogenic indices in pseudoexfoliation syndrome.

Enver Mirza1.   

Abstract

OBJECTIVES: Evaluation of atherogenic indices in patients with pseudoexfoliation syndrome (PEXS) by traditional serum lipid profiles [total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c), high-density lipoprotein cholesterol (HDL-c) and non-HDL-c] and non-traditional serum lipid ratios [TC/HDL-c, TG/HDL-c, LDL-c/HDL-c and non-HDL-c/HDL-c].
METHODS: A total of 100 patients were included in the study. Fifty patients diagnosed with PEXS were regarded as group 1 and 50 patients without PEXS were regarded as group 2, respectively.
RESULTS: The median TC, TG, LDL-c, HDL-c and non-HDL-c values were significantly higher in group 1 compared to group 2 (p = 0.007, p = 0.025, p = 0.016, p = 0.015 and p = 0.042, respectively). But there were no significant differences in the TC/HDL-c, TG/HDL-c, LDL-c/HDL-c and non-HDL-c/HDL-c ratios among the two groups (p = 0.581, p = 0.617, p = 0.292 and p = 0.583, respectively).
CONCLUSIONS: Non-traditional serum lipid ratios are superior to traditional serum lipid profiles for identifying the risk of vascular disease and this study did not demonstrate a complete relationship between PEXS and increased risk of vascular disease.

Entities:  

Year:  2019        PMID: 31278384      PMCID: PMC7002409          DOI: 10.1038/s41433-019-0506-z

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  45 in total

1.  Is pseudoexfoliation syndrome a risk factor for cardiovascular diseases?

Authors:  Mehmet Yokuşoğlu
Journal:  Anadolu Kardiyol Derg       Date:  2012-06-07

2.  Lipids and C-reactive protein as vascular risk markers in pseudoexfoliation syndrome.

Authors:  Hanna Lesiewska; Grażyna Malukiewicz; Aneta Mańkowska-Cyl; Grażyna Odrowąż-Sypniewska
Journal:  Acta Ophthalmol       Date:  2015-10-08       Impact factor: 3.761

Review 3.  [PEX syndrome. Clinical diagnosis and systemic manifestations].

Authors:  E Scharfenberg; U Schlötzer-Schrehardt
Journal:  Ophthalmologe       Date:  2012-10       Impact factor: 1.059

4.  Pseudoexfoliation syndrome and coronary artery ectasia.

Authors:  M O Akdemir; M R Sayin; M Armut; I Akpinar; S H Ugurbas
Journal:  Eye (Lond)       Date:  2014-03-07       Impact factor: 3.775

Review 5.  Light microscopy of the exfoliation syndrome.

Authors:  J C Morrison; W R Green
Journal:  Acta Ophthalmol Suppl       Date:  1988

Review 6.  Exfoliation syndrome and systemic cardiovascular diseases.

Authors:  Gábor Holló
Journal:  J Glaucoma       Date:  2014 Oct-Nov       Impact factor: 2.503

Review 7.  What have we learned about exfoliation syndrome since its discovery by John Lindberg 100 years ago?

Authors:  Samir Nazarali; Faraz Damji; Karim F Damji
Journal:  Br J Ophthalmol       Date:  2018-03-22       Impact factor: 4.638

8.  Cholesterol and coronary heart disease: predicting risks by levels and ratios.

Authors:  B Kinosian; H Glick; G Garland
Journal:  Ann Intern Med       Date:  1994-11-01       Impact factor: 25.391

9.  Usefulness of the high triglyceride-to-HDL cholesterol ratio to identify cardiometabolic risk factors and preclinical signs of organ damage in outpatient children.

Authors:  Procolo Di Bonito; Nicola Moio; Carolina Scilla; Luigi Cavuto; Gerolamo Sibilio; Eduardo Sanguigno; Claudia Forziato; Francesco Saitta; Maria Rosaria Iardino; Carla Di Carluccio; Brunella Capaldo
Journal:  Diabetes Care       Date:  2011-10-31       Impact factor: 19.112

10.  Association of lipid profiles and the ratios with arterial stiffness in middle-aged and elderly Chinese.

Authors:  Weiwei Zhao; Wei Gong; Nan Wu; Yintao Li; Kuanping Ye; Bin Lu; Zhaoyun Zhang; Shen Qu; Yiming Li; Yehong Yang; Renming Hu
Journal:  Lipids Health Dis       Date:  2014-02-20       Impact factor: 3.876

View more
  1 in total

1.  Prediagnostic Plasma Metabolomics and the Risk of Exfoliation Glaucoma.

Authors:  Jae H Kang; Oana Zeleznik; Lisa Frueh; Jessica Lasky-Su; A Heather Eliassen; Clary Clish; Bernard A Rosner; Louis R Pasquale; Janey L Wiggs
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-08-02       Impact factor: 4.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.